MCT unveils upgraded MBS Pool Optimizer using CUDA GPUs to deliver real-time, large-scale execution analysis and ...

Kyle Kirkwood keeps taking it to the streets in IndyCar, and this time he won a new race to take over the series lead. Kirkwood made an aggressive pass below four-time series champion Alex Palou with ...

Fans were gripping fences all Sunday morning as the sounds of racecars serenaded the tens of thousands who flocked to IndyCar’s inaugural Java House Grand Prix of Arlington. Kyle Kirkwood won the race ...

Kirkwood made an aggressive pass below four-time series champion Alex Palou with 15 laps to go, stayed in front the rest of the way and took the checkered flag for the Grand Prix of Arlington under ...

The Java House Grand Prix of Arlington, Texas, is the first of three new venues for the 2026 IndyCar Series season. Alex Palou and Josef Newgarden have won IndyCar Series races so far in 2026. The ...

REVIEW WAS CONDUCTED. KENDRA BROADUS JOINS US NOW. SO, KENDRA, WHAT DID THE REVIEW FIND? WELL, MARISSA, THE FIRST BOARD SAYS THAT INDEPENDENT REVIEW FOUND NO EVIDENCE OF MISCONDUCT BY DEAN KAMEN, BUT ...

AI-based discovery offers a new level of sophistication in surfacing content, without relying solely on keywords. Beyond keyword-string-first approaches, contextual and semantic elements are now more ...

First Brands Group and some of its creditors are weighing a shift of some of its units into the Chapter 7 bankruptcy liquidation process as the company runs low on cash, according to people familiar ...

The Pima County Sheriff’s Office didn’t immediately launch a high-tech aircraft at the start of the search for Savannah Guthrie’s missing mother, possibly hurting the investigation, according to a ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...